Recent comprehensive genomic studies have identified key molecular alterations in lower-grade gliomas, including mutations in IDH1/2, TP53, ATRX, and CIC genes, along with 1p/19q codeletion in oligodendrogliomas [5,6]. Here, TP53 is linked to central nervous system cancer.